Ameriprise Financial Inc Scynexis Inc Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $8,601 - $13,771	-4,700 Reduced 17.32%	22,440 $54,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $3.87 $1,063 - $2,325	-601 Reduced 2.17%	27,140 $50,000
Q1 2022 May 16, 2022	SELL	$3.56 - $6.66 $7,120 - $13,320	-2,000 Reduced 6.72%	27,741 $108,000
Q4 2021 Feb 14, 2022	SELL	$4.94 - $7.69 $263,356 - $409,961	-53,311 Reduced 64.19%	29,741 $181,000
Q3 2021 Nov 15, 2021	BUY	$5.3 - $7.89 $137,545 - $204,761	25,952 Added 45.45%	83,052 $440,000

Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $185,900 - $285,142	28,600 Added 100.35%	57,100 $420,000
Q1 2021 May 17, 2021	BUY	$6.93 - $9.63 $197,505 - $274,455	28,500 New	28,500 $226,000

15.4M

12.9K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $63.7M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.